Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China · Delayed Price · Currency is CNY 35.21
-0.44 (-1.23%)
May 14, 2026, 4:00 PM EDT
SHA:603014 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,713 | 3,705 | 3,535 | 3,454 | 3,294 | 2,778 |
Other Revenue | 63.56 | 63.56 | 69.49 | 78.52 | 131.76 | 132.56 |
| 3,777 | 3,769 | 3,604 | 3,532 | 3,426 | 2,911 | |
Revenue Growth (YoY) | 3.25% | 4.57% | 2.04% | 3.09% | 17.71% | - |
Cost of Revenue | 2,281 | 2,258 | 2,088 | 1,990 | 1,959 | 1,553 |
Gross Profit | 1,496 | 1,510 | 1,516 | 1,542 | 1,467 | 1,358 |
Selling, General & Admin | 768.55 | 789.8 | 801.06 | 857.25 | 884.67 | 841.65 |
Research & Development | 150.96 | 143.86 | 164.7 | 154.86 | 182.84 | 153.49 |
Other Operating Expenses | 33.96 | 32.24 | 16.58 | 32.02 | 41.75 | 6.27 |
Operating Expenses | 955.27 | 967.7 | 1,001 | 1,065 | 1,146 | 1,007 |
Operating Income | 540.37 | 542.65 | 514.85 | 477.11 | 320.93 | 350.7 |
Interest Expense | -0.74 | -0.74 | -0.6 | -0.85 | -18.33 | -47.58 |
Interest & Investment Income | 39.42 | 33.16 | 40.57 | 29.07 | 29.83 | 18.86 |
Currency Exchange Gain (Loss) | -3.34 | -3.34 | 2.73 | 2.38 | 7.53 | 3.63 |
Other Non Operating Income (Expenses) | 6.74 | 2.36 | -20.55 | 1.29 | 10.57 | -1 |
EBT Excluding Unusual Items | 582.46 | 574.09 | 536.99 | 509.01 | 350.53 | 324.6 |
Gain (Loss) on Sale of Investments | 1.71 | 0.99 | 0.22 | 0.11 | - | 2.18 |
Gain (Loss) on Sale of Assets | -0.01 | 0.02 | 0.2 | 0.09 | -0.01 | 0.01 |
Asset Writedown | -6.82 | -3.41 | -2.75 | -3.65 | - | -7.8 |
Other Unusual Items | 4.14 | 4.14 | 11.02 | 18.25 | 15.32 | 0.31 |
Pretax Income | 581.48 | 575.82 | 545.68 | 523.81 | 365.84 | 319.3 |
Income Tax Expense | 93.22 | 93.51 | 96.31 | 81.74 | 50.88 | 59.48 |
Earnings From Continuing Operations | 488.26 | 482.31 | 449.37 | 442.07 | 314.96 | 259.82 |
Minority Interest in Earnings | -0.01 | -0.01 | - | - | - | - |
Net Income | 488.24 | 482.3 | 449.37 | 442.07 | 314.96 | 259.82 |
Net Income to Common | 488.24 | 482.3 | 449.37 | 442.07 | 314.96 | 259.82 |
Net Income Growth | 6.70% | 7.33% | 1.65% | 40.36% | 21.22% | - |
Shares Outstanding (Basic) | 407 | 395 | 371 | 370 | 364 | 351 |
Shares Outstanding (Diluted) | 407 | 395 | 371 | 370 | 364 | 351 |
Shares Change (YoY) | 9.48% | 6.45% | 0.30% | 1.76% | 3.63% | - |
EPS (Basic) | 1.20 | 1.22 | 1.21 | 1.19 | 0.87 | 0.74 |
EPS (Diluted) | 1.20 | 1.22 | 1.21 | 1.19 | 0.87 | 0.74 |
EPS Growth | -2.54% | 0.83% | 1.68% | 37.47% | 16.98% | - |
Free Cash Flow | 569.24 | 633.86 | 393 | 55.33 | 447.53 | 103.64 |
Free Cash Flow Per Share | 1.40 | 1.60 | 1.06 | 0.15 | 1.23 | 0.29 |
Dividend Per Share | 0.518 | 0.518 | - | - | - | - |
Gross Margin | 39.60% | 40.08% | 42.06% | 43.67% | 42.83% | 46.65% |
Operating Margin | 14.31% | 14.40% | 14.29% | 13.51% | 9.37% | 12.05% |
Profit Margin | 12.93% | 12.80% | 12.47% | 12.52% | 9.19% | 8.93% |
Free Cash Flow Margin | 15.07% | 16.82% | 10.90% | 1.57% | 13.06% | 3.56% |
EBITDA | 782.21 | 782.76 | 748.08 | 708.36 | 553.87 | 542.22 |
EBITDA Margin | 20.71% | 20.77% | 20.76% | 20.05% | 16.17% | 18.63% |
D&A For EBITDA | 241.83 | 240.11 | 233.23 | 231.25 | 232.94 | 191.52 |
EBIT | 540.37 | 542.65 | 514.85 | 477.11 | 320.93 | 350.7 |
EBIT Margin | 14.31% | 14.40% | 14.29% | 13.51% | 9.37% | 12.05% |
Effective Tax Rate | 16.03% | 16.24% | 17.65% | 15.60% | 13.91% | 18.63% |
Revenue as Reported | 3,769 | 3,769 | 3,604 | 3,532 | 3,426 | 2,911 |
Advertising Expenses | - | - | - | 36.04 | 46.06 | 33.07 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.